Redefining the future
of thrombosis treatment

Advancing rapid onset, targeted and reversible therapies to build confidence in the treatment of life-threatening clots

For the latest company news and announcements, visit us on LinkedIn.

Leadership

Meet the leadership team driving Basking Biosciences’ vision

  • Julia C. Owens, PhD

    Julia C. Owens, PhD

    Chief Executive Officer
    Bio

  • Richard Shea, MBA

    President and Chief Operating Officer
    Bio

  • Shahid Nimjee, MD, PhD

    Shahid Nimjee, MD, PhD

    Founder and Chief Medical Officer
    Bio

  • Rob Hughes, MBA

    Rob Hughes, MBA

    Chief Financial Officer
    Bio

  • Stacy Nelson

    Stacy Nelson

    Vice President, Global Drug Development
    Bio

Our program in acute ischemic stroke

Basking’s lead candidate, BB-031, is being evaluated in an ongoing Phase II clinical trial in patients with acute ischemic stroke.  The investigational RNA aptamer targets von Willebrand Factor (vWF) to promote clot dissolution and restore blood flow to the brain. Together with its fast-acting reversal agent, BB-025, BB-031 is designed to improve the safety and control of thrombolytic therapy, with the goal of extending the treatment window and expanding access to care for more patients.

Clinicaltrials.gov